Saturday, 17 October 2026European Markets

ATLANTIC SAPPHIRE Stock Impressive Slide 10% So Far On Thursday, Underperforms Market

Loading stream...

(VIANEWS) - Shares of ATLANTIC SAPPHIRE (Oslo Børs Benchmark Index_GI: ASA.OL) fell by a staggering 10.9% to kr7.11 at 14:22 EST on Thursday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is dropping 1.67% to kr1,207.14, following the last session's downward trend. This seems, so far, an all-around down trend trading session today.

About ATLANTIC SAPPHIRE

Atlantic Sapphire ASA, together with its subsidiaries, engages in the land-based salmon farming business. It operates through two segments, Fish Farming (Denmark); and Fish Farming (US). The company is involved in the production and sale of salmon. It operates in the United States, Denmark, and internationally. The company was founded in 2010 and is headquartered in Vikebukt, Norway.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-4.74.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATLANTIC SAPPHIRE's stock is considered to be overbought (>=80).

More news about ATLANTIC SAPPHIRE (ASA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com